Trial reportTherapeutic advances in respiratory disease
Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough.
Trial report in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02612610 (A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough), which is not on this map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effect of Superior Laryngeal Nerve Block for Neurogenic Cough: A Single-Arm Meta-Analysis.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Pooled it
- Changes in quality of life of early-stage lung cancer patients undergoing sublobar resection: a systematic review.Frontiers in surgery · 2025Pooled it
- Pooled it
- The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial.BMC medicine · 2026Trial
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.Nature medicine · 2025Trial
- Psychometric validation of the severity of chronic cough diary, leicester cough questionnaire, and a cough severity visual analogue scale in patients with refractory chronic cough.Journal of patient-reported outcomes · 2025Trial
- Cough desensitization treatment for patients with refractory chronic cough: results of a second pilot randomized control trial.BMC pulmonary medicine · 2023Trial
- Article
- Article
- Article
- Prospective study to evaluate the effectiveness of guideline-based therapy for chronic cough and refractory chronic cough: PROCOUGH.ERJ open research · 2026Article
- Observational
- Article
- Cough Burden and Sleep Quality in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: A Cross-Sectional Study in Türkiye.Journal of clinical medicine · 2026Article
- Clinical impact and healthcare resource utilisation in patients with unexplained or refractory chronic cough: a French national population study.ERJ open research · 2026Article
- Health-Related Quality of Life in Chronic Cough: A Comparative Analysis With Other Chronic Diseases.Allergy, asthma & immunology research · 2026Article
- Clinical Efficacy of Acupuncture as Adjunctive Therapy for Cough Variant Asthma: Study Protocol for a Pilot Randomized Controlled Trial.Journal of asthma and allergy · 2026Article
- Telehealth group behavioural cough-suppression therapy for refractory chronic cough using a rolling enrolment model.ERJ open research · 2025Article
- Unmet need for biomarkers in chronic cough: a review of current challenges and future directions.ERJ open research · 2025Review
- Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial.EClinicalMedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Leicester Cough Questionnaire (LCQ), a cough-specific quality-of-life measure, evaluates the impact of cough across physical, psychological, and social domains in patients with chronic cough (CC). This study assessed the psychometric properties of the LCQ.
methodsData from a phase IIb, randomized controlled trial of the P2X3-receptor antagonist gefapixant were analyzed (NCT02612610). Subjective [Cough Severity Diary, cough severity visual analogue scale, and patient global impression of change (PGIC)] and objective (awake and 24-h cough frequency) data were used to validate the LCQ for use in patients with refractory or unexplained CC (RCC and UCC, respectively). Psychometric analyses included confirmatory factor analyses, internal consistency and test-retest reliability, validity, responsiveness, and estimated within-patient thresholds for clinically meaningful change.
resultsModel-fit values for the proposed three-factor LCQ domains and most individual items were acceptable. Analyses suggest that a mean improvement ranging from 1.3 to 2.3 points for the LCQ total and ⩾0.8, ⩾0.9, and ⩾0.8 points for physical, psychological, and social domain scores, respectively, had the best sensitivity and/or specificity for predicting patient ratings of improvement on the PGIC.
conclusionsThe LCQ is a valid and reliable measure to evaluate cough-specific quality of life and is a fit-for-purpose measure for use in patients with RCC or UCC. Although a single threshold for defining clinically meaningful change depends on the context of use, the results can help guide both treatment decisions and drug development. Therefore, clinicians may consider a ⩾1.3-point increase in the LCQ total score as clinically meaningful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.